| Bioactivity | Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research[1][2]. |
| Invitro | Tadocizumab (YM-337) 显着抑制体外 ADP 诱导的血小板聚集，并完全抑制花生四烯酸诱导的血小板聚集[1]。Tadocizumab (YM-337) 抑制人血小板粘附到 von Willebrand 因子、纤维蛋白原、纤连蛋白和内皮下基质[2]。 |
| In Vivo | Tadocizumab (YM-337; C4G1) 剂量依赖性地抑制离体血小板聚集，在恒河猴中以高于 0.25 mg/kg 静脉注射或 1.5 μg/kg/min 输注的剂量完全抑制[1]。在松鼠猴的光化学诱导血栓形成模型中，Tadocizumab (YM-337；C4G1) 以 1 mg/kg 的剂量静脉注射，然后以 6 μg/kg/min 的速度输注 60 分钟，可预防实验猴子的闭塞性血栓形成[1]。 |
| Name | Tadocizumab |
| CAS | 339086-80-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. S Kaku, et al. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys. Thromb Haemost. 1996 Apr;75(4):679-84. [2]. Ken-ichi Suzuki, et al. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties. Biol Pharm Bull. 2002 Aug;25(8):1006-12. |